Dendreon makes public offering

Dendreon Corp announced the pricing of an underwritten public offering of 10.7 million shares of its common stock. Deutsche Bank Securities,  which will act as sole manager for the offering, has been granted an  option to purchase an additional 1,279,166 shares of common stock to  cover over-allotments, if any.

Dendreon intends to use the net proceeds to develop manufacturing  facilities, a distribution network, an information technology platform  and other infrastructure, to hire sales and marketing, manufacturing,  quality and other personnel in preparation for the licensure by the  Food And Drug Administration and the commercialization of Provenge  (sipuleucel-T), and for general corporate purposes, including working  capital.